Introducing the *Journal of Hematology Oncology Pharmacy*

CO-EDITORS-IN-CHIEF
Patrick J. Medina, PharmD, BCOP¹; Val R. Adams, PharmD, BCOP, FCCP²
¹Associate Professor, Dept of Pharmacy, University of Oklahoma College of Pharmacy, Oklahoma City; ²Associate Professor, Pharmacy, and Program Director, PGY2, Specialty Residency Hematology/Oncology, University of Kentucky College of Pharmacy, Lexington

The *Journal of Hematology Oncology Pharmacy* (JHOP) seeks to provide hematology and oncology pharmacy practitioners and other hematology oncology professionals with high-quality peer-reviewed information to help them optimize drug therapy for patients. The journal will be split into four major sections.

*Original Research* will provide an outlet for translational and practice-based research, including case reports and case series. Our goal for this section is that these articles will answer the clinically relevant pharmacy questions that remain unaddressed. Many of which do not require a million-dollar extramural grant to answer, but that does not diminish the quality of the questions or the answers.

*Clinical Controversies* will discuss common clinical issues for which the treatment is not clear. On a daily basis, clinicians face clinical situations where decisions are made by extrapolating data to fit their clinical situation. Depending on which data are used to extrapolate or the interpretation of the situation, different therapeutic approaches may be taken. This section will include “point, counterpoint,” “roundtable discussion,” and “how I treat explanations” articles to describe the available data and how they are extrapolated into a therapeutic decision.

*Review Articles* will include manuscripts focusing not only on drugs and disease states but also on basic science reviews regarding the complex molecular biology of cancer. Although there is a plethora of review articles available to clinicians, most do not have a pharmacy focus, and few if any focus on the molecular biology of cancer and the complex signaling pathways associated with malignancy. As new classes of drugs emerge (eg, BRAF inhibitors), discussion about the pathways and the drugs targeting the pathways will help pharmacists understand the drug classes based on the pharmacology of these agents.

*Practical Issues in Pharmacy Management* will focus on real-world issues involving logistics, economics, and other practice-influencing topics. The section arguably has the greatest potential to fulfill an unmet hematology oncology pharmacy need by providing manuscripts on practice-related issues (eg, USP <797>, standing orders for new medications, justifying more pharmacy clinicians).

We are excited to publish the inaugural issue of *JHOP*. As pharmacy practice and research become integral both to improving the clinical care of cancer patients as well as to expanding the research literature in contemporary oncology pharmacy, new avenues are necessary to ensure this information gets disseminated to the profession.

We as the co-editors-in-chief hope that this journal will fill many unmet needs by providing another avenue for the publication of peer-reviewed, high-quality pharmacy literature that is focused for hematology oncology practitioners. We encourage you to submit manuscripts for consideration and to provide your feedback on what would enhance the value of this publication for you and your colleagues.

Please send manuscripts and comments to JHOP@greenhillhc.com.